Diagnostik und Therapie früher und fortgeschrittener Mammakarzinome

Adjuvante endokrine Therapie bei prä- und postmenopausalen Patientinnen
Adjuvante endokrine Therapie bei prä- und postmenopausalen Patientinnen

- Versionen 2002–2019:
  Bauerfeind / Dall / Diel / Fersis / Fehm / Friedrichs / Gerber / Göring / Hanf/ Harbeck / Huober / Jackisch / Lisboa / Lück / Lux / Maass / von Minckwitz / Möbus / Müller / Oberhoff / Schaller / Scharl / Schneeweiss / Schütz / Solomeyer / Stickeler / Thomssen / Untch/Fehm/Gerber

- Version 2020:
  Nitz / Huober
Endocrine responsiveness:


In case of ER negative / PR positive (>10% cells): consider immunohistochemical re-evaluation:

1. Viale G, Regan MM, Maiorano E et al. Prognostic and predictive value of centrally reviewed expression of estrogen and progesterone receptors in a randomized trial comparing letrozole and tamoxifen adjuvant therapy for postmenopausal early


8. Furlanetto J, Nekljudova V: Impact of chemotherapy-induced ovarian failure (CIOF) on disease –fee survival (dfs) and overall survival (osI in young women with early breast cancer, ESMO 2019 180 PD
8. Regan MM, Walley BA, Francis PA et al. Concurrent and sequential initiation of ovarian function suppression with chemotherapy

---

**Adjuvante endokrine Therapie**

<table>
<thead>
<tr>
<th>Endokrine Therapie:</th>
<th>Oxford LoE</th>
<th>GR</th>
<th>AGO</th>
</tr>
</thead>
<tbody>
<tr>
<td>Endokrin sensitiv</td>
<td>1a</td>
<td>A</td>
<td>++</td>
</tr>
<tr>
<td>fraglich endokrin sensitiv</td>
<td>3b</td>
<td>D</td>
<td>+</td>
</tr>
<tr>
<td>Endokrine Therapie sequentiell:</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>nach einer adjuvanten Chemotherapie</td>
<td>1a</td>
<td>A</td>
<td>++</td>
</tr>
<tr>
<td>Nicht endokrin sensitiv:</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>keine endokrine Therapie</td>
<td>1a</td>
<td>A</td>
<td>++</td>
</tr>
</tbody>
</table>

9. Villegas S, Lederer B: Similarities between low hormone receptor positive and hormone receptor negative breast cancer: an analysis of 4366 patients from multicenter clinical trials, SABCS 2018 P2-08-10
Tamoxifen 5-10 yrs:
GnRH as monotherapy:

Ovarian function suppression (OFS) with Tam/Al and Tam with or without OFS:
AI for first 5 years:

-Especially in case of lobular cancer
3. Strasser-Weippl K et al. Outcomes in women with invasive ductal or invasive lobular early stage breast cancer treated with anastrozole or exemestane in CCTG (NCIC CTG) MA.27. Eur J Cancer 2018;90:19-25. doi: 10.1016/j.ejca.2017.11.014

-High risk of recurrence:
Sequential therapy for first 5 years:
Tam (2-3 yrs.) followed by AI to complete 5 years
AI (2-3 yrs.) followed by Tam to complete 5 years


Tamoxifen 20 mg/d for first 5 yrs:

Patient care/ adherence and side effects


5 years Tamoxifen after 5 years Tamoxifen:


2–5 years AI after 5 years Tamoxifen in initially premenopausal patients with validated postmenopausal status in the course of therapy:


5 years Tamoxifen after 5 years Tamoxifen:


2–5 years AI after 5 years Tamoxifen

7. Gray R (EBCTCG ) et al. Extended aromatase inhibitor treatment following 5 or more years of endocrine therapy: a metaanalysis of 22192 women in 11 randomised trials. SABCS 2018;GS3-03
10. Del Mastro L, Masutti M: Benefit from letrozole as extended adjuvant therapy after sequential endocrine therapy: a randomized phase III trial of the Gruppo Italiano Mammella, ASCO 2019, abstract 505
11. Mamounas EP, Bandos H: Ten year results from NRG/NSABP – B42: a randomized , double blinded placebo controolle clinical trial of extended adjuvant endocrine therapy with letrozole in postmenopausal women with hormone receptor + breast cancer who have completed previuos adjuvant therapy with an aromatase inhibitor after initial AI containing therapy (upfront or switch) further prolongation of endocrine therapy with AI 2-5years. SABCS 2019, GS4-01
**low risk, poor tolerability of the AI**

6. Gray R (EBCTCG) et al. Extended aromatase inhibitor treatment following 5 or more years of endocrine therapy: a metaanalysis of 22192 women in 11 randomised trials. SABCS 2018;GS3-03

**Interruption of endocrine treatment up to 3 months during EAT:**

1. Gray R (EBCTCG) et al. Extended aromatase inhibitor treatment following 5 or more years of endocrine therapy: a metaanalysis of 22192 women in 11 randomised trials. SABCS 2018;GS3-03


10. Bartlett J, Sgroi DTrans-aTTom: Breast Cancer Index predicts benefit of extended endocrine therapy in HR+ breast cancers treated in the adjuvant tamoxifen-to offer meore (aTTom) trial Abstract 505 ASCO 2019
Ovarian function protection


Pregnancy rates


Fertility preservation counselling


Fertility preservation with assisted reproduction therapy


## Adjuvante endokrine Therapie im Überblick

<table>
<thead>
<tr>
<th>Studie</th>
<th>Therapie</th>
<th>Def-facto-Verlängerung (Jahre)</th>
<th>HB für DFS</th>
<th>AI-Therapie (Jahre)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Jahre nach Diagnose</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>0</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>2</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>3</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>4</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>5</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>6</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>7</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>8</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>9</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>10</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>15</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Studies with Tamoxifen nach 5 Jahren Tamoxifen</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>ATLAS</td>
<td></td>
<td>5 vs 10</td>
<td>0.75 − 0.99</td>
<td>0</td>
</tr>
<tr>
<td>ATOM</td>
<td></td>
<td>5 vs 10</td>
<td>0.75 − 0.99</td>
<td>0</td>
</tr>
<tr>
<td>Studies with AI nach 5 Jahren Tamoxifen</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>MA 17</td>
<td></td>
<td>5 vs 10</td>
<td>0.17 − 0.68</td>
<td>0</td>
</tr>
<tr>
<td>NOA93 B/33</td>
<td></td>
<td>5 vs 10</td>
<td>0.68 − 0.62</td>
<td>0</td>
</tr>
<tr>
<td>ABCSG 42</td>
<td></td>
<td>5 vs 8</td>
<td>0.62 − 0.62</td>
<td>0</td>
</tr>
<tr>
<td>Studies with anerkannter AI TR, nach 5 Jahren endokrin inkl. AI</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>DAXA</td>
<td></td>
<td>6 vs 9</td>
<td>0.79 − 100</td>
<td>100</td>
</tr>
<tr>
<td>NSAR 8/47</td>
<td></td>
<td>5 vs 10</td>
<td>0.45 − 100</td>
<td>100</td>
</tr>
<tr>
<td>MA 12R</td>
<td></td>
<td>10 vs 15</td>
<td>0.66 − 100</td>
<td>100</td>
</tr>
<tr>
<td>Studies with optimaler Dauer in Jahr 5-10</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>ROSSI 2006-06</td>
<td></td>
<td>7.5 vs 10</td>
<td>0.92 − 88</td>
<td>88</td>
</tr>
<tr>
<td>IDEAL</td>
<td></td>
<td>7.5 vs 10</td>
<td>1.007 − 49</td>
<td>49</td>
</tr>
</tbody>
</table>

**Legende:**
- **Braun:** Tamoxifen, Grün: Tamoxifen oder AI, Blau: AI
- **Gestreift, Zeit der randomisierten Intervention vs keine Therapie od. Plazebo,**
- ***: Randomisierungszeitpunkt,**
- **$: MA17R nach 5 Jahren AI mit /ohne Tam zuvor**